Publications by authors named "Sarah B Lesesne"
Background: In the United States, hepatitis C virus (HCV) infection is most prevalent among adults born from 1945 through 1965, and approximately 50% to 75% of infected adults are unaware of their infection.
Objective: To estimate the cost-effectiveness of birth-cohort screening.
Design: Cost-effectiveness simulation.
Objectives: Information on the process and method of service delivery is sparse for hepatitis B surface antigen (HBsAg) testing, and no systematic study has evaluated the relative effectiveness or cost-effectiveness of different HBsAg screening models. To address this need, we compared five specific community-based screening programs.
Methods: We funded five HBsAg screening programs to collect information on their design, costs, and outcomes of participants during a six-month observation period.
Article Synopsis
- Many patients with untreated chronic hepatitis C will develop severe liver disease and face high mortality rates.
- The study forecasts the future impact of hepatitis C from 2010 to 2060, predicting an increase in end-stage liver disease cases, transplants, and deaths, especially peaking around 2030-2035.
- Without enhanced screening and treatment efforts, the burden of hepatitis C is expected to rise significantly in the coming years.
The Centers for Disease Control and Prevention recommends hepatitis B surface antigen (HBsAg) testing to identify chronic hepatitis B virus infection for foreign-born persons from countries or regions with HBsAg prevalence of >or=2%. However, limited data exist to indicate which countries meet this definition. To address this data gap, we estimated the HBsAg prevalence among refugees entering the United States between 2006 and 2008.
View Article and Find Full Text PDFObjective: To forecast age-related macular degeneration (AMD) and its consequences in the United States through the year 2050 with different treatment scenarios.
Methods: We simulated cases of early AMD, choroidal neovascularization (CNV), geographic atrophy (GA), and AMD-attributable visual impairment and blindness with 5 universal treatment scenarios: (1) no treatment; (2) focal laser and photodynamic therapy (PDT) for CNV; (3) vitamin prophylaxis at early-AMD incidence with focal laser/PDT for CNV; (4) no vitamin prophylaxis followed by focal laser treatment for extra and juxtafoveal CNV and anti-vascular endothelial growth factor treatment; and (5) vitamin prophylaxis at early-AMD incidence followed by CNV treatment, as in scenario 4.
Results: Cases of early AMD increased from 9.